Evidence map›Paper›PMID 41605691›Full record

Observational studyEndocrine journal2026

Use, efficacy, and safety of desmopressin for congenital nephrogenic diabetes insipidus in children: a nationwide survey.

Kento Ikegawa, Masanobu Fujimoto, Kohei Aoyama, Hirofumi Nakayama, Takuo Kubota, Keisuke Nagasaki, Setsuko Naganuma, Makoto Ono, Shinji Higuchi, Haruo Mizuno and 5 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Endocrine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kento IkegawaDivision of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.ORCID http://orcid.org/0000-0001-7053-7004
Masanobu FujimotoDivision of Pediatrics and Perinatology, Faculty of Medicine, Tottori University, Tottori, Japan.ORCID http://orcid.org/0000-0002-8604-7517
Kohei AoyamaDepartment of Pediatrics and Neonatology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.
Hirofumi NakayamaDepartment of Pediatrics, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Takuo KubotaDepartment of Pediatrics, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Keisuke NagasakiDivision of Pediatrics, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Setsuko NaganumaDepartment of Pediatrics, Kumamoto Rosai Hospital, Kumamoto, Japan.
Makoto OnoDepartment of Pediatrics, Chiba Kaihin Municipal Hospital, Chiba, Japan.
Shinji HiguchiDivision of Pediatric Endocrinology, Metabolism, and Nephrology, Osaka City General Hospital, Osaka, Japan.
Haruo MizunoDepartment of Pediatrics, Fujita Health University School of Medicine, Aichi, Japan.
Susumu KanzakiAsahigawaso Rehabilitation and Medical Center, Okayama, Japan.
Yoshihiko MorikawaClinical Research Support Center, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Masataka HondaClinical Research Support Center, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Naoko AmanoDivision of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Yukihiro HasegawaDivision of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Congenital nephrogenic diabetes insipidus (CNDI) is characterized by resistance of the distal nephrons and collecting ducts to arginine vasopressin (AVP). High doses of 1-deamino-8-D-arginine vasopressin (DDAVP), a V2-receptor-selective agonist, are effective in some cases. The present study aimed to demonstrate the use, efficacy, and safety of DDAVP and the characteristics of patients who responded to this treatment. The present, retrospective, multicentric, observational survey of patients with CNDI receiving DDAVP was based on a previous, nationwide survey conducted by the Japanese Society for Pediatric Endocrinology (JSPE) and collected data on the use (formulation, dosage, and treatment duration), efficacy (change in urine output and height SDS), and safety of DDAVP. In the initial survey, 43 of 123 JSPE council members (35.0%) observed the patients. The secondary survey of 13 patients found DDAVP to be effective in five patients (38.5%), as evidenced by a 12.6-31.6% decrease in urine output. The maximum urine osmolality on a water deprivation test and urine osmolality after vasopressin injection were lower in patients who were unresponsive to DDAVP than in those who were responsive to the drug (106 vs. 206 mOsm/H

Indexed as

Antidiuretic AgentsDeamino Arginine VasopressinDiabetes Insipidus, NephrogenicChildChild, PreschoolFemaleHumansInfantJapanMaleOsmolar ConcentrationReceptors, VasopressinRetrospective StudiesTreatment OutcomeAntidiuretic AgentsDeamino Arginine VasopressinReceptors, Vasopressin1-deamino-8-D-arginine vasopressinArginine vasopressin resistanceChildrenCongenital nephrogenic diabetes insipidusDesmopressin

Identifiers

PMID41605691
PMCPMC13195454

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.